Inovio announces positive data from phase 2 segment of clinical trial evaluating ino-4800, its covid-19 dna vaccine

Plymouth meeting, pa., may 10, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded phase 2 segment of its phase 2/3 clinical trial in the u.s., called innovate ( in ovio i no -4800 va ccine t rial for e fficacy), evaluating ino-4800, its dna vaccine candidate for covid-19.
INO Ratings Summary
INO Quant Ranking